Inadequate response to targeted immunomodulators for rheumatoid arthritis may lead to significantly higher economic burden, including higher health care resource utilization. READ MORE

News

The prevalence of rheumatic immune-related adverse events in 524 patients with cancer who received immune checkpoint inhibitors was 6.6%, according to a single-center observational study published in Annals of the Rheumatic Diseases.

READ MORE

Approximately 40% of patients with rheumatoid arthritis with persistent moderate to high disease activity waited at least 90 days for adjustment of their DMARD therapy.

READ MORE

An international expert group has issued consensus-based recommendations on the use of biosimilars for rheumatologic diseases, focusing on cost, extrapolation, and switching between bio-originators and biosimilars.

READ MORE

Research in Review

A study of the biologic drug ustekinumab has found it to be a better treatment for psoriasis than tumor necrosis factor-alpha (TNF-α) inhibitors.

READ MORE

Guidelines for rheumatoid arthritis formulated by a panel of patients had most of the same recommendations as those developed by a panel of physicians.

READ MORE